CD19 and leukemia: We thus exposed leukemic (defined as ≥15% of all CD45+/SSlow cells displaying the CD5+/CD19+ immunophenotype of CLL cells and/or having a spleen volume of ≥200 μl) TC (median age of 31.8 ± 4.0 weeks at treatment initiation) and TCA mice (median age of 23.6 ± 6.1 weeks at treatment initiation) to olaparib (50 mg/kg, intraperitoneally (i.p.)on 5 days/week) and assessed leukemia progression through flow cytometry-based quantification of CD5+/CD19+ leukemic cells in the blood stream and MRI-based quantification of spleen volume, as a surrogate marker for lymphadenopathy.